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REVIEW
Abstract: Restenosis after endovascular treatment of atherosclerotic lesions in the peripheral,
cerebrovascular, and coronary circulation is the major drawback of this minimally invasive
technique. Although certain advances have been made during recent years to improve patency
rates after percutaneous angioplasty, restenosis remains a challenging clinical problem.
Understanding factors that contribute to the pathophysiology of late lumen loss is an effective
strategy to improving patients’ postangioplasty outcome. Vascular inflammation after balloon
angioplasty or stent implantation has been identified as a cornerstone of the restenotic process,
and several markers of inflammation have been referred to as potential predictors of outcome.
This article reviews recent findings on the issue of inflammation and restenosis after
percutaneous angioplasty with special attention given to the role of inflammatory parameters
as markers for the restenosis risk in the peripheral vessel area.
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Introduction
Percutaneous transluminal angioplasty (PTA) is a minimally invasive revascularization
procedure for treatment of atherosclerotic lesions in the peripheral, cerebrovascular,
and coronary vessel area. Late clinical failure after primarily successful interventions
due to recurrent stenosis (restenosis) occurring in up to 60% of the patients within
the first 12 months remains the major drawback of percutaneous angioplasty and
limits a widespread application of this minimally invasive technique (Gallino et al
1984; Krepel et al 1985; Maca et al 1996; Minar et al 1998; Cejna et al 2001; Exner
et al 2001; Schillinger et al 2001). As competitive surgical approaches yield better
long-term results, the indications for endovascular revascularisation are a matter of
debate (Diegeler et al 2002). Furthermore, with increasing numbers of procedures
performed, late sequelae due to recurrent stenoses and the need for costly
reinterventions become more frequent. Understanding the factors that contribute to
the pathophysiology of late lumen loss is the foundation to develop effective strategies
for improvement of patients’ postangioplasty outcome. Endovascular brachytherapy
(Minar et al 1998, 2000) and the upcoming drug eluting stents (Sousa et al 2001;
Suzuki et al 2001; Morice et al 2002) are suggested to reduce the rate of intermediate
term restenosis in the peripheral as well as in the coronary vessel area, but selection
criteria for patients who are candidates for these expensive procedures with limited
availability are indeterminate. Once identified, reliable predictors of the restenosis
risk could facilitate the targeted use of measures for prevention of restenosis and
help to save healthcare resources.
Accumulating data indicate that insights gained from the link between
inflammation and restenosis can yield predictive and prognostic information of
considerable clinical utility. Inflammation in the vessel wall in response to balloon
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injury or stent implantation initiates hypertrophic neointima
formation through vascular smooth muscle cell (VSMC)
proliferation and constrictive vascular remodelling (O’Brian
and Schwartz 1994; Ross 1999; Orford et al 2000). This
process of neointima formation and recurrent lumen
narrowing has been referred to as manifestation of an
inflammatory wound healing response expressed
specifically in vascular tissue (Forrester et al 1991). The
present article reviews recent findings on the issue of
inflammation and restenosis with special attention to the
peripheral vessel area.
Pathophysiology of inflammation
and restenosis
Chronic vascular inflammation is involved in the
development of restenosis after balloon angioplasty and stent
implantation (Forrester et al 1991; Belch et al 1997; Serrano
et al 1997; Kamijikkoku et al 1998; Kornowski et al 1998;
Tsakiris et al 1999; Yutani et al 1999; Lusis 2000; Cippolone
et al 2001; Glass and Witztum 2001; Schillinger et al 2001,
2002a; Libby et al 2002). Broadly, restenosis can be
considered to be a form of hypertrophic wound healing
resulting from an interaction between monocyte-derived
macrophages, T cells, and the normal cellular elements of
the arterial wall. A triggering event for the vascular
inflammatory process is shear stress during balloon inflation
or stent implantation and vascular injury, which stimulate
the production of proinflammatory molecules and activation
of circulating monocytes (Serrano et al 1997). Expression
of selectins and adhesion molecules mediate the binding of
circulating monocytes and penetration of these cells into
the vascular wall (Ross 1999; Lusis 2000; Glass and Witztum
2001; Libby et al 2002). The magnitude of monocyte
activation and adherence to the vascular wall was suggested
to promote late lumen loss (Pietersma et al 1995; Mickelson
et al 1996). The first step in adhesion of inflammatory cells
at the dilated or stented segment, the “rolling” of leucocytes,
is mediated by selectins, which bind to carbohydrate ligands
on leukocytes. The E-selectin serum level, for example, has
been demonstrated to closely correlate with the restenosis
risk (Belch et al 1997). The firm adhesion of monocytes
and T cells to the arterial wall is then mediated via cell
adhesion molecules (CAMs); CAMs have also been shown
to be associated with the restenotic process (Kamijikkoku
et al 1998; Tsakiris et al 1999). Once adherent to the
endothelium, the monocytes penetrate into the intima and
through the media to the adventitia (Wilcox et al 2001).
Monocyte chemotactic protein-1 (MCP 1) appears
responsible for monocyte recruitment and direct
transmigration into the vascular wall at the treated lesion,
and higher serum levels of this chemokine indicate a higher
restenosis risk (Cipollone et al 2001). Once resident in the
arterial wall, the blood-derived inflammatory cells
participate in and perpetuate a local inflammatory response.
Inflammatory molecules as well as shear stress during the
endovascular procedure stimulate the immigration of
VSMCs from the medial layer of the arterial wall past the
internal elastic lamina and into the intimal or subendothelial
space. Recruitment and proliferation of myofibroblasts and
synthesis of extracellular matrix proteins are key factors of
hypertrophic neointima formation and restenosis (Wilcox
et al 2001). This phase of lesion progression is markedly
influenced by interactions between monocyte/macrophages
and T cells, which results in the acquisition of many features
of a chronic inflammatory state.
Predictive value of inflammatory
markers and acute phase proteins
Acute phase reactants are related to atherosclerosis in the
peripheral, coronary, and extracranial brain arteries
(Heinrich et al 1995; Tschöpl et al 1997; Blum et al 1998;
Buffon et al 1999; Schillinger et al 2002b, 2003a, 2003b).
These circulating markers of inflammation reflect the
activity of the disease associated with accumulation of
macrophages and proliferation of endothelial cells and
vascular smooth muscle cells (Haverkate et al 1997). The
plasma proteins, C-reactive protein (CRP), serum amyloid
A (SAA), and fibrinogen are sensitive, specific, and fast
reacting markers of acute phase reaction (Pepys and Baltz
1983; Young et al 1991; Ernst 1993) and provide an indirect
measure of a cytokine dependent inflammatory process of
the arterial wall (Pepys 1995; Kuller et al 1996). Balloon
injury and stent implantation in the peripheral vessel area
have been demonstrated to induce a vascular inflammatory
response at the dilated vessel segment, which is measurable
by the postintervention course of serum acute phase
parameters like CRP, SAA, or fibrinogen (Schillinger et al
2002c), and the severity of arterial injury during balloon
injury or stent placement correlated with increased
inflammation (Virmani and Farb 1999).
It is well known that patency rates after percutaneous
transluminal angioplasty and stent implantation widely
depend on the location of the treated lesion. Endovascular
treatment of large elastic arteries like the internal carotidVascular Health and Risk Management 2005:1(1) 75
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artery and the iliac arteries is associated with a relatively
low rate of recurrence (Bosch et al 1997; Tetteroo et al 1998;
Dormandy and Rutherford 2000; Ahmadi et al 2001). In
contrast, in the muscular conduit arteries of the
femoropopliteal segment restenosis after PTA more
frequently occurs (Adar et al 1989; Jeans et al 1990; Matsi
et al 1994; Dormandy and Rutherford 2000). Thus, it seemed
reasonable to speculate that these differences of restenosis
rates may be due to differences of the extent of inflammation
in response to endovascular treatment. Indeed, it could be
shown that stent implantation in the muscular arteries of
the femoropopliteal segment was associated with a more
extensive vascular inflammatory response than stenting of
the elastic iliac or carotid arteries, suggesting that the
enhanced inflammatory response after femoropopliteal
stenting might contribute to the higher rates of restenosis in
this vessel area (Schillinger et al 2002d). Nevertheless, the
predictive value of acute phase reactants remained to be
demonstrated.
Recently, several studies evaluated the prognostic impact
of inflammatory laboratory parameters and the potential
clinical relevance to predict the individual’s restenosis risk.
It was consistently shown that elevated baseline values and
postintervention levels of these inflammatory parameters
were associated with an increased risk for restenosis after
peripheral, coronary, and carotid angioplasty (Tschöpl et al
1997; Blum et al 1998; Buffon et al 1999; Schillinger et al
2001, 2002a, 2002b, 2003a, 2003b). Elevated CRP levels
are an indicator of increased cardiovascular risk in healthy
individuals as well as in patients with atherosclerosis (Berk
et al 1990; Liuzzo et al 1994; Heinrich et al 1995; Kuller et
al 1996; Mendall et al 1996; Haverkate et al 1997). Low
level chronic inflammatory activity in the vascular tissue is
suggested to cause a CRP elevation in patients with
atherosclerosis (Mendall et al 1996), reflecting the activity
of the disease. Higher peri-procedure CRP values are thus
thought to indicate a higher activity of the disease and an
increased susceptibility for hypertrophic vascular
remodeling and excessive neointima formation after
percutaneous angioplasty. However, it remains indeterminate
whether acute phase reactants are only indicators of an
increased risk for restenosis or causally contribute to its
occurrence. One mechanism of a causal role could be the
activation of the complement system, local vascular
inflammatory reactions, and subsequent tissue damage
(Torzewski et al 1998). Furthermore, CRP at concentrations
known to predict adverse vascular events decreases nitric
oxide synthesis and inhibits angiogenesis (Verma et al 2002);
both factors are markedly involved in the pathogenesis of
vascular disease.
The crucial question remains, whether acute phase
reactants like CRP will be clinically useful to predict the
individual’s risk for restenosis. Currently, clear cut-off levels
of CRP indicating an increased restenosis risk are lacking,
and routine application of these inflammatory parameters
therefore seems not to be justified.
Inflammatory and antiinflammatory
genes: involvement in restenosis?
Recent research has focused on the potential implications
of genetic variability on the pathophysiology of vascular
disease (Jukema et al 2000; Kastrati et al 2000; Bauters et
al 2001; Roguin et al 2001). Traditional risk factors for
recurrent lumen narrowing after percutaneous angioplasty
– like local hemodynamics or technical success – account
for only a minor proportion of the restenosis risk, and genetic
predisposition seems to markedly influence the individual’s
susceptibility for this process (Exner et al 2001). In
particular, genes encoding for inflammatory or anti-
inflammatory proteins are suggested to play a pivotal role
in the pathophysiology of lesion recurrence. Several
candidate genes have been investigated so far. Briefly,
genetic variability may be found in most of the genes
encoding for the inflammatory parameters mentioned above:
interleukins, selectins, CAMs etc. Variable expression of
almost all of these factors may influence the extent of
vascular inflammation in response to percutaneous
angioplasty, and thus the occurrence of restenosis. However,
results of most observational studies demonstrating an
association between a genetic characteristic and the
restenosis risk have to be interpreted cautiously – type II
errors or false positive findings are likely to occur in small
patient series.
Exemplary, two specific gene polymorphisms may be
discussed that are potentially involved in the patho-
physiology of restenosis in the peripheral vessel area: the
heme oxygenase 1 (HO-1) genotype, as an antiinflammatory
factor; and the interleukin 6 (IL-6) genotype, as an
inflammatory polymorphism. Heme oxygenase-1 (HO-1)
is a novel vascular protective factor with potent
antiinflammatory and antioxidant effects and the ability to
inhibit the proliferation of smooth muscle cells (Maines
1988; Tenhunen et al 1989; Duckers et al 2001; Ishikawa et
al 2001; Tulis et al 2001). Development of restenosis in largeVascular Health and Risk Management 2005:1(1) 76
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measure involves these very factors that are inhibited by
HO-1: inflammation in the vessel wall, constrictive vascular
remodeling, and hypertrophic neointima formation through
smooth muscle cell proliferation.
HO-1 is up-regulated by balloon angioplasty. However,
humans differ quantitatively in their ability to mount a
HO-1 response. There is a length polymorphism in the form
of a (GT)n dinucleotide repeat in the 5´-flanking region of
the human HO-1 gene that modulates the quantitative level
of HO-1 activity in response to a given stimulus (Kimpara
et al 1997; Yamada et al 2000). The HO-1 promoter genotype
was associated with the postintervention inflammatory
response and the occurrence of restenosis after
femoropopliteal PTA (Exner et al 2001, Schillinger et al
2002e, 2004). Patients with a certain genotype of the HO-1
gene promoter exhibited a lower postintervention
inflammatory response and a lower restenosis rate at
6 months compared with non-carriers of this genetic variant.
This suggested that a stronger HO-1 response is protective
against restenosis. Modulation of the postintervention
vascular inflammatory response seemed to be an underlying
mechanism of the protective effect of HO-1 up-regulation
after balloon angioplasty.
Interleukin 6, on the other hand, represents a key factor
in the vascular inflammatory cascade after balloon injury
that is directly involved in the regulation of the acute phase
response. A functional polymorphism in the IL-6 gene
promoter has been demonstrated to modulate the cytokine
expression in response to vascular injury (Brull et al 2001).
Consistently, this IL-6 promoter polymorphism was
associated with the 12 months restenosis risk after
femoropopliteal PTA in a larger patient series (Exner et al
2004), indicating a potential involvement of pro-
inflammatory genes in the restenotic process. Nevertheless,
future research will have to focus on more complex
gene–gene and gene–environment interactions, since
restenosis likely is a polygenetic process and may not be
explained by a single genetic polymorphism.
Potential clinical implications
Some experimental data indicate that modulation or
suppression of the inflammatory response after endovascular
treatment may exert beneficial effects on outcome. Statins
are known to exert potent antiinflammatory properties and
have been demonstrated to reduce inflammation and
progression of atherosclerosis. In this context, it has been
recently demonstrated that a statin (pitavastatin) has the
ability to inhibit neointimal hyperplasia after stenting in a
procine coronary model mainly through a reduction of
inflammatory reactions (Yokoyama 2004). Furthermore, in
patients with persistently high CRP levels after successful
coronary artery stent implantation, oral immunosuppressive
therapy with prednisone resulted in a striking reduction of
clinical events and angiographic restenosis rate (Versaci et
al 2002). In contrast to these conventional pharmacological
approaches, various gene therapeutic approaches also
seemed promising. In hypercholesterolemic rabbits, local
adenovirus-mediated I kappa B alpha gene transfer had the
potential to reduce intimal hyperplasia after stent placement
(Breuss et al 2002; Cejna et al 2002). Similarly, pre-
treatment with recombinant antibodies against leukocyte
P-selectin glycoprotein ligand-1, a key factor of
inflammation and activation of platelets, in a porcine
coronary stent model reduced neointimal proliferation and
in-stent restenosis (Tanguay et al 2004). Another
experimentally successful gene-therapeutic approach to
inhibit inflammation and reduce restenosis was the recently
described inhibition of early growth response factor 1 in
hypercholesterolemic rabbits after carotid balloon injury
(Ohtani et al 2004).
Conclusion
Evidence from experimental, animal, and clinical studies
support the hypothesis that vascular inflammation is a key
factor in the restenotic process. The extent of vascular
inflammation in response to percutaneous angioplasty
predicts the restenosis risk, although currently inflammatory
markers are not of clinical utility in this context. Variability
in genes encoding for vascular inflammatory and
antiinflammatory genes is worth further examination with
regard to the pathophysiology of recurrent lumen narrowing.
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